Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide, cutting the monthly price to $349, earlier than expected, for people willing to ...

The UK-US deal does not resolve every challenge – no single agreement could. But it marks a meaningful step toward restoring ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singaporean Health Sciences Authority (HSA) say the ...

Drug delivery is no longer just about convenience. It’s about enabling the therapies of the future to succeed where they ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...

Regeneron has been a bit of a latecomer in the market for BCMA-directed therapies for multiple myeloma, but is pushing to catch up with rival therapies from Johnson & Johnson and Pfizer. At ASH, ...

Less than two years after buying Chinese biotech Gracell for its cell therapy platform, AstraZeneca has reported encouraging clinical results with the lead CAR-T from the deal, GC012F (now AZD0120), ...

A court in Munich has granted a preliminary injunction that will prevent MSD from distributing the subcutaneous version of its cancer immunotherapy Keytruda in the German market. The verdict is the ...

Hundreds of people with a rare and aggressive form of leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after it was recommended for routine commissioning by the NHS.

Otsuka has claimed FDA approval for its IgA nephropathy (IgAN) therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch. Anti-APRIL antibody Voyxact ...